---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086369"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:37:42.986252+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fennec appoints Jeffrey Hackman as CEO, succeeding Rostislav Raykov

## Summary
- Hackman named CEO and director effective August 16, 2024; Raykov steps down after 15 years, remains on board.
- Hackman's initial salary $550,000, target bonus 50% of salary, granted 400,000 options vesting over three years.
- Raykov enters separation agreement; acceleration of 292,359 options at weighted avg price $7.50; RSUs intact through April 2027.
- Hackman brings 30+ years commercial oncology experience; previously led U.S. operations at Sigma Tau, Baxalta, Shire, EUSA Pharma.
- Appointment comes as company expands PEDMARK use for cisplatin-induced ototoxicity in pediatric and AYA patients.

## SEC filing metadata
- accession: 0001104659-24-086369
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/tm2421051d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086369
- JSON: https://secwatch.observer/filing/0001104659-24-086369.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086369.txt

## Key facts
- Executive change
  Rostislav Raykov departed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..
  - Action: depart
  - Role: Chief Executive Officer
  source text: the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm
- Executive change
  Jeffrey S. Hackman was appointed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm
- Executive change
  Jeffrey S. Hackman was appointed as Director at FENNEC PHARMACEUTICALS INC..
  - Action: appointed
  - Role: Director
  source text: the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.